Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex.

OBJECTIVES The aim of the present study was to evaluate and assess the in vitro activity of eight drugs, including the new azole isavuconazole, against 81 strains representing 13 species of the Fusarium fujikuroi species complex. METHODS A total of 81 Fusarium spp. isolates, within the F. fujikuroi species complex, were identified by molecular methods and tested according to CLSI M38-A2. Eight antifungal compounds, including the new azole isavuconazole, were tested. Isolates were selected to represent the widest variety of geographical regions and to include clinical as well as environmental strains. RESULTS Susceptibility profiles differed between and within species, with Fusarium verticillioides showing the lowest MICs and Fusarium nygamai the highest MICs. Amphotericin B was the most active drug, followed by voriconazole, posaconazole, isavuconazole and natamycin. The remaining antifungals (fluconazole, itraconazole and micafungin) showed poor activity with MIC/minimum effective concentration values of ≥ 32, ≥ 16 and >8 mg/L, respectively. CONCLUSIONS Resistance patterns in the F. fujikuroi species complex are species specific and therefore identification down to species level is important for the choice of antifungal treatment.

[1]  G. S. de Hoog,et al.  Taxonomy and Clinical Spectra of Fusarium Species: Where Do We Stand in 2014? , 2014, Current Clinical Microbiology Reports.

[2]  T. Lietman,et al.  Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. , 2014, Ophthalmology.

[3]  M. Caira,et al.  European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  L. Pagano,et al.  ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  T. Anagnostou,et al.  Fusarium Infection , 2013, Medicine.

[6]  A. Chowdhary,et al.  Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health , 2013, PLoS pathogens.

[7]  Springer-Verlag,et al.  Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  M. Srinivasan,et al.  Organism, Minimum Inhibitory Concentration, and Outcome in a Fungal Corneal Ulcer Clinical Trial , 2012, Cornea.

[9]  J. Meis,et al.  Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria Species , 2012, Antimicrobial Agents and Chemotherapy.

[10]  E. Mylonakis,et al.  The challenge of managing fusariosis , 2011, Virulence.

[11]  J. Guarro,et al.  In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum , 2008, Antimicrobial Agents and Chemotherapy.

[12]  T. Peláez,et al.  In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species , 2008, Antimicrobial Agents and Chemotherapy.

[13]  J. Guarro,et al.  Universal In Vitro Antifungal Resistance of Genetic Clades of the Fusarium solani Species Complex , 2007, Antimicrobial Agents and Chemotherapy.

[14]  D. Loebenberg,et al.  In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.

[15]  J. Graybill,et al.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. J. Buitrago,et al.  Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi , 2006, Antimicrobial Agents and Chemotherapy.

[17]  M. Klepser,et al.  In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole against Aspergillus, Fusarium, and Scedosporium spp , 2005, Antimicrobial Agents and Chemotherapy.

[18]  A. Espinel-Ingroff.  In Vitro Fungicidal Activities of Voriconazole, Itraconazole, and Amphotericin B against Opportunistic Moniliaceous and Dematiaceous Fungi , 2001, Journal of Clinical Microbiology.

[19]  J. Guarro,et al.  In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. , 1997, The Journal of antimicrobial chemotherapy.